BioCryst Pharmaceuticals, Inc.
Rank #3HypergrowthBCRX · Nasdaq · Healthcare
BioCryst Pharmaceuticals, Inc. (BCRX) — Rank #3 by gross profitability (GP/assets 1.53) · ROE -58.1% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0000882796 · all metrics point-in-time as of the filing date.
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Show moreShow less
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc.
was founded in 1986 and is headquartered in Durham, North Carolina.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- biocryst.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowdeteriorating
- Gross marginstable
- Gross profitabilitystable
- Net cashn/a
- Operating marginstable
- Return on equitydeteriorating
- Share count (dilution)improving
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2017-12-31filed 2018-03-12 | 2016-12-31filed 2017-02-27 | 2015-12-31filed 2016-02-26 | 2014-12-31filed 2015-03-02 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 25.2 | 26.4 | 48.3 | 13.6 |
| Revenue growth (YoY) | -4.4% | -45.4% | 254.6% | -21.5% |
| Gross profit | 24.0 | 24.1 | 46.9 | 13.6 |
| Gross margin | 95.5% | 91.3% | 97.2% | 100.0% |
| Net income | (65.8) | (55.1) | (43.0) | (45.2) |
| Net margin | -261.2% | -209.3% | -89.1% | -332.1% |
| Cash flow | ||||
| Operating cash flow | (41.1) | (53.4) | (13.1) | (38.6) |
| Capital expenditures | 0.3 | 5.3 | 5.1 | 0.1 |
| Free cash flow | (41.5) | (58.7) | (18.2) | (38.7) |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?